

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcements of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) dated 24 April 2016 and 28 April 2016 (the “**Announcements**”) in relation to the acquisition of 51% equity interest in SJKGC involving the issue of Consideration Shares under Specific Mandate. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, it was expected that a circular (the “**Circular**”) containing, among other things, further details of the Acquisition and the Specific Mandate, together with notice of Class Meetings and other information as required under the GEM Listing Rules is expected to be despatched to the Shareholders on or before 16 May 2016. As additional time is required for the Company to prepare and finalise the information to be included in the Circular, in particular, the valuation report in respect of the assets of SJKGC, the despatch of the Circular will be delayed to on or before 30 June 2016.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
16 May 2016

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Wang Shuxin; the non-executive Directors of the Company are Feng Enqing, Chen Yingzhong and Ou Linfeng; the independent non-executive Directors of the Company are Guan Tong, Wu Chen and Peter K.S. Chan.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain at the “Latest Company Announcements” page on the GEM website at www.hkgem.com for at least seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com